Govt Invites Pharma Firms to Submit Data for Ceiling Price Review

Published On 2025-05-17 15:09 GMT   |   Update On 2025-05-17 15:09 GMT

New Delhi: The Department of Pharmaceuticals (DoP), under the Ministry of Chemicals and Fertilizers, has invited pharmaceutical manufacturers to apply for revision of ceiling prices for eligible scheduled formulations. The move applies to drugs already listed under the National List of Essential Medicines (NLEM), 2022 and also present in NLEM 2015, in line with paragraph 18 of the Drugs (Prices Control) Order, 2013 (DPCO).

Advertisement

In its latest circular, the Department stated, “In accordance with the provisions of para 18(i) of Drugs (Prices Control) Order, 2013, the Department of Pharmaceuticals invites applications for revision of ceiling prices for the scheduled formulations as specified under NLEM, 2022 which were also included in NLEM, 2015.”

As per Para 18(i) of DPCO, 2013, “The Government may revise the ceiling price of scheduled formulations as specified under the First Schedule after the expiry of one year from the date of fixing the ceiling price of such scheduled formulations.”

This price revision process offers an opportunity for manufacturers to submit fresh data reflecting updated market dynamics. However, the scope is limited to those formulations which have already been under price control for over a year.

Manufacturers are instructed to apply only through the online portal, “Applications for revision of ceiling prices may be submitted only through Integrated Pharmaceutical Database Management System (IPDMS) portal at https://ipdms.gov.in in the prescribed Format.”

The notice further clarifies that, “Applications without supporting data shall not be considered.”

To view the official notice, click on the link below:

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News